mCRPC (Metastatic Castration-resistant Prostate Cancer) research hub

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

This study looks at a new drug combination, Gedatolisib and Darolutamide, for men with prostate cancer that has spread and is no longer responding to standard hormone therapy. It helps work out the best dose and how well it works.